This is one reason not to recommend its use presently as a substitute for PMMA in vertebral reinforcement procedures.”
“Therapeutic monoclonal antibodies (mAbs) possess a high degree of heterogeneity associated with the cell expression system employed in manufacturing, most

notably glycosylation. Traditional immunoassay formats used to quantify therapeutic mAbs C59 molecular weight are unable to discriminate between different glycosylation patterns that may exist on the same protein amino acid sequence. Mass spectrometry provides a technique to distinguish specific glycosylation patterns of the therapeutic antibody within the same sample, thereby allowing for simultaneous quantification of the same mAb with different glycosylation patterns. Here we demonstrate a two-step approach to successfully differentiate and quantify serum mixtures of a recombinant therapeutic mAb produced in two different host cell lines (CHO vs. Sp2/0) with distinct glycosylation profiles. Glycosylation analysis of

the therapeutic mAb, CNTO 328 (siltuximab), was accomplished through sample pretreatment consisting of immunoaffinity purification (IAP) and enrichment, followed by liquid chromatography ZD1839 molecular weight (LC) and mass spectrometry (MS). LC-MS analysis was used to determine the percentage of CNTO 328 in the sample derived from either cell line based on the N-linked G1F oligosaccharide on the mAb. The relative amount of G1F derived from each cell line was compared with ratios of CNTO 328 reference standards prepared in buffer. Glycoform ratios were converted to concentrations using an immunoassay measuring total CNTO 328 that does not distinguish between the different

glycoforms. Validation of the IAP/LC-MS method included intra-run and inter-run variability, method sensitivity and freeze-thaw stability. The method was accurate (% bias range = -7.30-13.68%) and reproducible (% CV range = 1.49-10.81%) with a LOQ of DMH1 cell line 2.5 mu g/mL.”
“A case of a female patient with thalidomide-induced phocomelia and additional dermal complications associated with the prosthesis itself is presented herein.”
“As the production volume of biodiesel grows, conventional raw materials used in the production of biodiesel, such as rapeseed oil, are lacking, and other potentially oleaginous plants, the oil of which could be used for production of biodiesel, must be investigated. This article addresses opportunities for chufa sedge cultivation and presents the quality indicators for chufa sedge oil and the biodiesel derived from it. The results show that chufa sedge oil may be used directly in biodiesel production, and the biodiesel produced from chufa sedge oil complies with the requirements of the standards in almost all properties except for oxidation stability and cold filter plugging point.